Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic ...

BofA downgraded Zai Lab (ZLAB) to Neutral from Buy with a price target of $36.10, up from $29. The firm cites the growth slowdown of the company’s core products and its belief that Zai’s near ...

Goldman Sachs analysts added Zai Lab (ZLAB) to the firm’s APAC Conviction List as part of its monthly update. The firm says the company is transitioning from a licensing-in based China-only ...

Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License Application for TIVDAK, ...

JPMorgan raised the firm’s price target on Zai Lab (ZLAB) to $51 from $44 and keeps an Overweight rating on the shares. The firm updated models in the small-cap biotechnology space. Published ...

Scotiabank initiated coverage on shares of Zai Lab (NASDAQ:ZLAB – Free Report) in a research note issued to investors on ...